Setegis® (Setegis®)

Like other antagonists of alpha-adrenergic receptors, terazosin It is not recommended to appoint patients with syncope during urination in the anamnesis.

After the first dose and the first days of therapy, the "first dose" effect may develop: a marked drop in blood pressure, in particular, orthostatic hypotension (with dizziness, sensation of loss of consciousness, fainting). Hypovolemia and restriction of salt intake increase the risk of the effect of the first dose. The same phenomenon can be observed with the resumption of treatment after several days of interruption, therefore, in such cases, the initial dose should be re-applied. The frequency of fainting is approximately 1% of cases. In addition to the effect of the "first dose", too rapid increase in the dose and simultaneous use of diuretics and other antihypertensive drugs can also cause syncope. Syncope, as a rule, is due to pronounced orthostatic hypotension, but it can also be associated with tachycardia (120-160 beats / min). Orthostatic hypotension is most pronounced soon after taking the drug, and the risk of developing fainting is highest between the 30th and 90th minutes after taking the drug. Change of position from the horizontal position or sitting position, long stay in standing position, intense physical load,high ambient temperatures and simultaneous intake of alcohol can provoke dizziness, a sense of insecurity, or even loss of consciousness. If the patient faints, it should be laid with raised lower limbs, and if necessary, apply other variants of symptomatic therapy. When terazosin is used together with diuretics and / or other antihypertensive agents, its dose should be reduced. To avoid severe hypotension, it is recommended to begin treatment with the concomitant drug also with low doses and to conduct careful medical supervision of the patient. The same precautions are necessary when adding terazosin to current diuretic therapy or antihypertensive therapy. The initial dose of terazosin in these cases is also 1 mg.

In elderly patients, sensitivity to the hypotensive effect of terazosin may be increased. The use of terazosin requires extreme caution in patients with a predisposition to orthostatic hypotension, ischemic heart disease, other severe heart diseases, cerebral circulation, grade III or IV hypertensive retinopathy, insulin-dependent diabetes, and impaired hepatic and renal function.Before the beginning of terazosin treatment of benign prostatic hyperplasia, prostatic carcinoma should be excluded. The patient's blood pressure should be measured regularly at the beginning of treatment with hypertrophy of the prostate with terazosin, in the case of additional therapy, with increasing the dose; also should take into account simultaneously taken antihypertensive drugs. The effectiveness of terazosin in benign prostatic hyperplasia can be assessed only after 4-6 weeks of maintenance dose. In the case of an operation to remove cataracts, patients who received prior alpha-1 blockers experience intraoperative iris of the irisIFIS). This phenomenon is a variant of the narrow pupil syndrome, in which the iris relaxes to such an extent that it becomes unstable during irrigation.

Despite the preoperative dilatation of the pupil, usually with the help of mydriatic means, the miosis intensifies, and the iris sags toward the phacoemulsification incisions. In such cases, the operating surgeon should be prepared to change the technique of the operation,You may need to use a hook for the iris-coated shell, iris retractor and viscoelastic substances. Preoperative. interruption of therapy αl-blockers has no advantage compared to the continuation of therapy.

Tablets contain lactose monohydrate (55 mg or 110 mg), so patients with galactose intolerance, lactase deficiency, or with glucose malabsorption syndrome and galactose should not take this drug.